Zobrazeno 1 - 10
of 549
pro vyhledávání: '"KENSEI YAMAGUCHI"'
Autor:
Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, Kensei Yamaguchi, Tomohiro Nishina, Elena Elez, Javier Rodriguez, Ian Chau, Maria Di Bartolomeo, Hisato Kawakami, Fumitaka Suto, Makito Koga, Koichiro Inaki, Yusuke Kuwahara, Issey Takehara, Daniel Barrios, Kojiro Kobayashi, Axel Grothey, Takayuki Yoshino
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract DESTINY-CRC01 (NCT03384940) was a multicentre, open-label, phase 2 study that investigated the safety and efficacy of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing metastatic color
Externí odkaz:
https://doaj.org/article/26bade50fd904d768b662d98f645dae3
Autor:
Hiroki Osumi, Eiji Shinozaki, Yoshiaki Nakamura, Taito Esaki, Hisateru Yasui, Hiroya Taniguchi, Hironaga Satake, Yu Sunakawa, Yoshito Komatsu, Yoshinori Kagawa, Tadamichi Denda, Manabu Shiozawa, Taroh Satoh, Tomohiro Nishina, Masahiro Goto, Naoki Takahashi, Takeshi Kato, Hideaki Bando, Kensei Yamaguchi, Takayuki Yoshino
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract “NeoRAS WT” refers to the loss of RAS mutations (MTs) following first-line treatment in metastatic colorectal cancer (mCRC). We evaluate the incidence and clinicopathological characteristics of NeoRAS WT mCRC using next-generation sequen
Externí odkaz:
https://doaj.org/article/32159db2ff3a4f6f8eaee8f39adf3f96
Autor:
Koshiro Fukuda, Hiroki Osumi, Koichiro Yoshino, Izuma Nakayama, Shota Fukuoka, Mariko Ogura, Takeru Wakatsuki, Akira Ooki, Daisuke Takahari, Keisho Chin, Kensei Yamaguchi, Eiji Shinozaki
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Few studies have focused on the impact of single-organ pulmonary metastases on progression-free survival and overall survival in patients with metastatic colorectal cancer. Recognizing differences in prognosis and chemotherapeutic
Externí odkaz:
https://doaj.org/article/d13b8dce74d849dab9090169595d05c9
Autor:
Takayuki Yoshino, Maria Di Bartolomeo, Kanwal Raghav, Toshiki Masuishi, Fotios Loupakis, Hisato Kawakami, Kensei Yamaguchi, Tomohiro Nishina, Zev Wainberg, Elena Elez, Javier Rodriguez, Marwan Fakih, Fortunato Ciardiello, Kapil Saxena, Kojiro Kobayashi, Emarjola Bako, Yasuyuki Okuda, Gerold Meinhardt, Axel Grothey, Salvatore Siena, DESTINY-CRC01 investigators
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after ≥2 prio
Externí odkaz:
https://doaj.org/article/b78d3fdfa83149b6a91ce6f79897ff81
Autor:
Aya Nishizawa, Eiji Shinozaki, Takeru Wakatsuki, Takahiro Satoh, Naoya Yamazaki, Shunsuke Oyamada, Keisuke Ariyoshi, Kota Kihara, Masahiro Tsuboi, Kensei Yamaguchi
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-7 (2023)
Abstract Background Regorafenib, a multikinase inhibitor, causes a high frequency of hand-foot skin reactions (HFSRs). The present study evaluated the efficacy of topical aluminum chloride, a perspiration suppressant, in reducing the severity of hand
Externí odkaz:
https://doaj.org/article/f015af072078406e892195341eb78f9f
Autor:
Izuma Nakayama, Eiji Shinozaki, Hiroshi Kawachi, Takashi Sasaki, Mayu Yunokawa, Junichi Tomomatsu, Takeshi Yuasa, Satoru Kitazono, Kokoro Kobayashi, Keiko Hayakawa, Arisa Ueki, Shunji Takahashi, Kensei Yamaguchi
Publikováno v:
Cancer Medicine, Vol 12, Iss 7, Pp 7932-7940 (2023)
Abstract Background In Japan, microsatellite instability (MSI) testing for solid tumors was introduced in clinical practice in December 2018. Although immune checkpoint inhibitors (ICIs) are established standards of care for patients with MSI‐high
Externí odkaz:
https://doaj.org/article/9b96c2e100c24760ba571998e28d756d
Clinicopathological characteristics of advanced gastric cancer after Helicobacter pylori eradication
Autor:
Junki Tokura, Ken Namikawa, Kaoru Nakano, Yoshitaka Tokai, Shoichi Yoshimizu, Yusuke Horiuchi, Akiyoshi Ishiyama, Toshiyuki Yoshio, Toshiaki Hirasawa, Souya Nunobe, Kensei Yamaguchi, Hiroshi Kawachi, Junko Fujisaki
Publikováno v:
JGH Open, Vol 6, Iss 12, Pp 833-838 (2022)
Abstract Background and Aim Helicobacter pylori (H. pylori) eradication has become popular as it prevents the development of gastric cancer. There have been no comprehensive studies on advanced gastric cancer (AGC) after eradication; thus, the clinic
Externí odkaz:
https://doaj.org/article/11c4b4d8b0884646ba6d319fab6ba078
Autor:
Hiroki Osumi, Atsuo Takashima, Akira Ooki, Yuri Yoshinari, Takeru Wakatsuki, Hidekazu Hirano, Izuma Nakayama, Natsuko Okita, Ryoichi Sawada, Kota Ouchi, Koshiro Fukuda, Shota Fukuoka, Mariko Ogura, Daisuke Takahari, Keisho Chin, Hirokazu Shoji, Ken Kato, Naoki Ishizuka, Narikazu Boku, Kensei Yamaguchi, Eiji Shinozaki
Publikováno v:
Translational Oncology, Vol 35, Iss , Pp 101718- (2023)
Purpose: As circulating tumor DNA (ctDNA) measurement becomes more widespread, the “NeoRAS” phenomenon, where tissue rat sarcoma viral oncogene homolog (RAS) status converts from mutant (MT) to wild-type (WT) after treatment in metastatic colorec
Externí odkaz:
https://doaj.org/article/2dd4356f4b714e61ada692c8cdb096f1
Autor:
Akira Ooki, Satoshi Morita, Akihito Tsuji, Shigeyoshi Iwamoto, Hiroki Hara, Hiroaki Tanioka, Hironaga Satake, Masato Kataoka, Masahito Kotaka, Yoshinori Kagawa, Masato Nakamura, Tatsushi Shingai, Masashi Ishikawa, Yasuhiro Miyake, Takeshi Suto, Yojiro Hashiguchi, Taichi Yabuno, Masahiko Ando, Junichi Sakamoto, Kensei Yamaguchi
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Purpose Although early tumor shrinkage (ETS) is a predictor of improved overall survival (OS), the association between ETS and health-related quality of life (HRQOL) remains unclear for patients with metastatic colorectal cancer (mCRC) treat
Externí odkaz:
https://doaj.org/article/8e277a2749b9411aa5325e80e6e2203a
Autor:
Akira Ooki, Taroh Satoh, Kei Muro, Atsuo Takashima, Shigenori Kadowaki, Daisuke Sakai, Takashi Ichimura, Seiichiro Mitani, Toshihiro Kudo, Keisho Chin, Shigehisa Kitano, Dung Thai, Marianna Zavodovskaya, JieJane Liu, Narikazu Boku, Kensei Yamaguchi
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Andecaliximab (ADX) is a monoclonal antibody that inhibits matrix metalloproteinase 9 (MMP9), an extracellular enzyme involved in matrix remodeling, tumor growth, and metastasis. In preclinical models, MMP9 inhibitors have been shown to enha
Externí odkaz:
https://doaj.org/article/47b63337491a4ba288e5e4723a34c5c6